FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890312600> ?p ?o ?g. }

• W2890312600 endingPage "3037" @default.
• W2890312600 startingPage "3037" @default.
• W2890312600 abstract "3037 Background: PD-L1 can be induced by IFNG in tumor cells (TC) and immune cells (IC). TC PD-L1 expression prevalence in UC is low and the relevance of scoring TC (in addition to IC) is not fully understood. We recently reported a positive correlation between high levels of an IFNGS and outcome in a cohort of 30 UC pts treated with D. Here, we assessed the potential predictive value of the IFNGS in an additional 32 pts (total N = 62) and further explored the relationship between the IFNGS and TC and/or IC PD-L1 IHC expression patterns. Methods: Study CP1108 was a phase 1/2 trial evaluating D in pts with solid tumors; 191 UC pts received 10 mg/kg D with median follow up of 8.4 mo. 144 of these pts have available ORR and PD-L1 data and 62 pts have ORR, PD-L1 and IFNGS data. Pts with ≥25% TC or IC were scored as PD-L1 high (TC+ or IC+). Pts within the top tertile of IFNGS ( LAG3, PDL1, CXCL9, and IFNG mRNAs) tumor expression were scored positive. Cox proportional hazards models were used adjusting for age, gender, ECOG, smoking status, line of therapy, and liver metastasis at baseline. ORR was evaluated using RECIST v1.1. Results: IFNGS+ pts had increased ORR (45 vs 16%) and improved PFS (adj HR 0.3; p = 0.005) and OS (adj HR 0.18; p = 0.016) over IFNGS- pts. IFNGS expression was significantly higher in pts who were PD-L1 high (TC+/IC+) compared with TC-/IC- (low/negative) pts (mean IFNGS expression 3.5 vs 1.1; p = 0.0155) and also in TC+ or IC+ vs TC-/IC- (mean IFNGS 2.2 vs 1.1; p = 0.000127). TC-/IC+ and TC+/IC- groups had a mean IFNGS expression of 2 and 2.2 respectively. ORR in all 1108 UC pts with available IHC and ORR data (N = 144) was 29% for TC+/- pts, 36% in TC-/IC+ pts, and 7% in the TC-/IC- pts. Conclusions: IFNGS predicted improved outcomes in a cohort of 62 2L+ UC pts treated with D. TC-/IC- PD-L1 pts had lowest levels of IFNGS expression. Observations that TC+ (and IC+) pts contribute to IFNGS enrichment and that TC+/IC-, and TC-/IC+ pts have increased response vs TC-/IC-pts provides rationale for TC+ inclusion (in addition to IC+) in the SP263 PD-L1 scoring algorithm for UC. IFNGS is an additional potential predictive biomarker in UC pts that warrants further investigation." @default.
• W2890312600 created "2018-09-27" @default.
• W2890312600 creator A5001771767 @default.
• W2890312600 creator A5003817127 @default.
• W2890312600 creator A5009504777 @default.
• W2890312600 creator A5010379826 @default.
• W2890312600 creator A5021748826 @default.
• W2890312600 creator A5024465677 @default.
• W2890312600 creator A5029143856 @default.
• W2890312600 creator A5031609759 @default.
• W2890312600 creator A5036760632 @default.
• W2890312600 creator A5043124797 @default.
• W2890312600 creator A5045318953 @default.
• W2890312600 creator A5046158954 @default.
• W2890312600 creator A5051762151 @default.
• W2890312600 creator A5072333489 @default.
• W2890312600 creator A5073857588 @default.
• W2890312600 creator A5076873642 @default.
• W2890312600 date "2017-05-20" @default.
• W2890312600 modified "2023-10-03" @default.
• W2890312600 title "Biologic and clinical relevance of an IFNG mRNA signature (IFNGS) and PD-L1 protein expression in tumor and immune cells in urothelial cancer (UC) patients (pts) treated with durvalumab (D)." @default.
• W2890312600 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3037" @default.
• W2890312600 hasPublicationYear "2017" @default.
• W2890312600 type Work @default.
• W2890312600 sameAs 2890312600 @default.
• W2890312600 citedByCount "6" @default.
• W2890312600 countsByYear W28903126002018 @default.
• W2890312600 countsByYear W28903126002019 @default.
• W2890312600 countsByYear W28903126002020 @default.
• W2890312600 crossrefType "journal-article" @default.
• W2890312600 hasAuthorship W2890312600A5001771767 @default.
• W2890312600 hasAuthorship W2890312600A5003817127 @default.
• W2890312600 hasAuthorship W2890312600A5009504777 @default.
• W2890312600 hasAuthorship W2890312600A5010379826 @default.
• W2890312600 hasAuthorship W2890312600A5021748826 @default.
• W2890312600 hasAuthorship W2890312600A5024465677 @default.
• W2890312600 hasAuthorship W2890312600A5029143856 @default.
• W2890312600 hasAuthorship W2890312600A5031609759 @default.
• W2890312600 hasAuthorship W2890312600A5036760632 @default.
• W2890312600 hasAuthorship W2890312600A5043124797 @default.
• W2890312600 hasAuthorship W2890312600A5045318953 @default.
• W2890312600 hasAuthorship W2890312600A5046158954 @default.
• W2890312600 hasAuthorship W2890312600A5051762151 @default.
• W2890312600 hasAuthorship W2890312600A5072333489 @default.
• W2890312600 hasAuthorship W2890312600A5073857588 @default.
• W2890312600 hasAuthorship W2890312600A5076873642 @default.
• W2890312600 hasConcept C121608353 @default.
• W2890312600 hasConcept C126322002 @default.
• W2890312600 hasConcept C143998085 @default.
• W2890312600 hasConcept C203014093 @default.
• W2890312600 hasConcept C2777701055 @default.
• W2890312600 hasConcept C2777742743 @default.
• W2890312600 hasConcept C2780030458 @default.
• W2890312600 hasConcept C2781053074 @default.
• W2890312600 hasConcept C50382708 @default.
• W2890312600 hasConcept C71924100 @default.
• W2890312600 hasConcept C72563966 @default.
• W2890312600 hasConcept C8891405 @default.
• W2890312600 hasConcept C90924648 @default.
• W2890312600 hasConceptScore W2890312600C121608353 @default.
• W2890312600 hasConceptScore W2890312600C126322002 @default.
• W2890312600 hasConceptScore W2890312600C143998085 @default.
• W2890312600 hasConceptScore W2890312600C203014093 @default.
• W2890312600 hasConceptScore W2890312600C2777701055 @default.
• W2890312600 hasConceptScore W2890312600C2777742743 @default.
• W2890312600 hasConceptScore W2890312600C2780030458 @default.
• W2890312600 hasConceptScore W2890312600C2781053074 @default.
• W2890312600 hasConceptScore W2890312600C50382708 @default.
• W2890312600 hasConceptScore W2890312600C71924100 @default.
• W2890312600 hasConceptScore W2890312600C72563966 @default.
• W2890312600 hasConceptScore W2890312600C8891405 @default.
• W2890312600 hasConceptScore W2890312600C90924648 @default.
• W2890312600 hasIssue "15_suppl" @default.
• W2890312600 hasLocation W28903126001 @default.
• W2890312600 hasOpenAccess W2890312600 @default.
• W2890312600 hasPrimaryLocation W28903126001 @default.
• W2890312600 hasRelatedWork W1411054225 @default.
• W2890312600 hasRelatedWork W2596040508 @default.
• W2890312600 hasRelatedWork W2745896026 @default.
• W2890312600 hasRelatedWork W3104817578 @default.
• W2890312600 hasRelatedWork W3144899533 @default.
• W2890312600 hasRelatedWork W3175985098 @default.
• W2890312600 hasRelatedWork W4304808194 @default.
• W2890312600 hasRelatedWork W4309244132 @default.
• W2890312600 hasRelatedWork W4311192294 @default.
• W2890312600 hasRelatedWork W4366351644 @default.
• W2890312600 hasVolume "35" @default.
• W2890312600 isParatext "false" @default.
• W2890312600 isRetracted "false" @default.
• W2890312600 magId "2890312600" @default.
• W2890312600 workType "article" @default.